Current Immunological and Clinical Perspective on Vaccinations in Multiple Sclerosis Patients: Are They Safe After All?

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2021 Apr 30

PMID 33917860

Citations 10

Authors

Shani Witman Tsur

Eli Adrian Zaher

Meydan Tsur

Karolina Kania

Alicja Kalinowska-Lyszczarz

Affiliations

Soon will be listed here.

Abstract

Vaccines work by stimulating the immune system, and their immunogenicity is key in achieving protection against specific pathogens. Questions have been raised whether in Multiple Sclerosis (MS) patients they could induce disease exacerbation and whether vaccines could possibly act as a trigger in the onset of MS in susceptible populations. So far, no correlation has been found between the vaccinations against influenza, hepatitis B, tetanus, human papillomavirus, measles, mumps, rubella, varicella zoster, tuberculosis, yellow fever, or typhoid fever and the risk of MS. Further research is needed for the potential protective implications of the tetanus and Bacillus Calmette-Guerin vaccines in MS patients. Nowadays with the emerging coronavirus disease 2019 (COVID-19) and recent vaccinations approval and arrival, the risk-benefit in MS patients with regards to safety and efficacy of COVID-19 vaccination in those treated with immunosuppressive therapies is of paramount importance. In this manuscript, we demonstrate how different vaccine types could be related to the immunopathogenesis of MS and discuss the risks and benefits of different vaccinations in MS patients.

Citing Articles

The impact of social and environmental factors on triggering multiple sclerosis onset, before and during the COVID-19 pandemic: a retrospective study from Iran.

Kasbi N, Ghadiri F, Naser Moghadasi A, Khodaie F, Kohandel K, Rezaeimanesh N BMC Neurol. 2024; 24(1):453.

PMID: 39563293 PMC: 11575067. DOI: 10.1186/s12883-024-03956-x.

Vaccination status and self-reported side effects after SARS-CoV-2 vaccination in relation to psychological and clinical variables in patients with multiple sclerosis.

Burian K, Heidler F, Frahm N, Hecker M, Langhorst S, Mashhadiakbar P Sci Rep. 2024; 14(1):12248.

PMID: 38806524 PMC: 11133397. DOI: 10.1038/s41598-024-62541-x.

Occurrence and Risk Factors of Relapse Activity after Vaccination against COVID-19 in People with Multiple Sclerosis: 1-Year Follow-Up Results from a Nationwide Longitudinal Observational Study.

Fneish F, Frahm N, Peters M, Ellenberger D, Haas J, Lobermann M Vaccines (Basel). 2023; 11(12).

PMID: 38140262 PMC: 10747540. DOI: 10.3390/vaccines11121859.

Vaccine response in people with multiple sclerosis treated with fumarates.

Tremblay M, Vukusic S, Shanmugasundaram M, Bozin I, Levin S, Gocke A Mult Scler J Exp Transl Clin. 2023; 9(3):20552173231191170.

PMID: 37692293 PMC: 10483985. DOI: 10.1177/20552173231191170.

Cellular and Molecular Evidence of Multiple Sclerosis Diagnosis and Treatment Challenges.

Khan Z, Gupta G, Mehan S J Clin Med. 2023; 12(13).

PMID: 37445309 PMC: 10342392. DOI: 10.3390/jcm12134274.

References

Huang W, Chen W, Zhang X . Multiple sclerosis: Pathology, diagnosis and treatments. Exp Ther Med. 2017; 13(6):3163-3166. PMC: 5450788. DOI: 10.3892/etm.2017.4410. View

Ergonul O, Egeli D, Kahyaoglu B, Bahar M, Etienne M, Bleck T . An unexpected tetanus case. Lancet Infect Dis. 2016; 16(6):746-752. DOI: 10.1016/S1473-3099(16)00075-X. View

Kieseier B . The mechanism of action of interferon-β in relapsing multiple sclerosis. CNS Drugs. 2011; 25(6):491-502. DOI: 10.2165/11591110-000000000-00000. View

Zilber N, Kahana E . Risk factors for multiple sclerosis: a case-control study in Israel. Acta Neurol Scand. 1996; 94(6):395-403. DOI: 10.1111/j.1600-0404.1996.tb00051.x. View

McCarthy C, Tuohy O, Compston D, Kumararatne D, Coles A, Jones J . Immune competence after alemtuzumab treatment of multiple sclerosis. Neurology. 2013; 81(10):872-6. PMC: 3885219. DOI: 10.1212/WNL.0b013e3182a35215. View

DeStefano F, Verstraeten T, Jackson L, Okoro C, Benson P, Black S . Vaccinations and risk of central nervous system demyelinating diseases in adults. Arch Neurol. 2003; 60(4):504-9. DOI: 10.1001/archneur.60.4.504. View

Louapre C, Collongues N, Stankoff B, Giannesini C, Papeix C, Bensa C . Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. JAMA Neurol. 2020; 77(9):1079-1088. PMC: 7320356. DOI: 10.1001/jamaneurol.2020.2581. View

Sormani M . An Italian programme for COVID-19 infection in multiple sclerosis. Lancet Neurol. 2020; 19(6):481-482. PMC: 7191287. DOI: 10.1016/S1474-4422(20)30147-2. View

Manouchehrinia A, Tanasescu R, Kareem H, Jerca O, Jabeen F, Shafei R . Prevalence of a history of prior varicella/herpes zoster infection in multiple sclerosis. J Neurovirol. 2017; 23(6):839-844. PMC: 5725504. DOI: 10.1007/s13365-017-0569-1. View

10.

Bankamp B, Hickman C, Icenogle J, Rota P . Successes and challenges for preventing measles, mumps and rubella by vaccination. Curr Opin Virol. 2019; 34:110-116. DOI: 10.1016/j.coviro.2019.01.002. View

11.

Kappos L, Mehling M, Arroyo R, Izquierdo G, Selmaj K, Curovic-Perisic V . Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis. Neurology. 2015; 84(9):872-9. DOI: 10.1212/WNL.0000000000001302. View

12.

Wang R, Pan W, Jin L, Huang W, Li Y, Wu D . Human papillomavirus vaccine against cervical cancer: Opportunity and challenge. Cancer Lett. 2019; 471:88-102. DOI: 10.1016/j.canlet.2019.11.039. View

13.

Naismith R, Cross A . Does the hepatitis B vaccine cause multiple sclerosis?. Neurology. 2004; 63(5):772-3. DOI: 10.1212/01.wnl.0000137887.24504.30. View

14.

Langley L, Zeicu C, Whitton L, Pauls M . Acute disseminated encephalomyelitis (ADEM) associated with COVID-19. BMJ Case Rep. 2020; 13(12). PMC: 10577777. DOI: 10.1136/bcr-2020-239597. View

15.

Staples J, Gershman M, Fischer M . Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010; 59(RR-7):1-27. View

16.

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

17.

Mailand M, Frederiksen J . Vaccines and multiple sclerosis: a systematic review. J Neurol. 2016; 264(6):1035-1050. DOI: 10.1007/s00415-016-8263-4. View

18.

Eberhardson M, Hall S, Papp K, Sterling T, Stek J, Pang L . Safety and Immunogenicity of Inactivated Varicella-Zoster Virus Vaccine in Adults With Autoimmune Disease: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Clin Infect Dis. 2017; 65(7):1174-1182. DOI: 10.1093/cid/cix484. View

19.

Gasperini C, Ruggieri S . Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approach. Drug Des Devel Ther. 2012; 6:175-86. PMC: 3414371. DOI: 10.2147/DDDT.S8927. View

20.

Ryder E, Steelman A . Does upper respiratory infection exacerbate symptoms of multiple sclerosis?. Future Microbiol. 2018; 13:503-505. DOI: 10.2217/fmb-2017-0271. View